



Published in final edited form as:

Am J Med Genet A. 2018 October ; 176(10): 2070–2081. doi:10.1002/ajmg.a.40504.

Molecular genetics of 22q11.2 deletion syndrome

Bernice E. Morrow^{1,*}, Donna M. McDonald-McGinn², Beverly S. Emanuel², Joris R. Vermeesch³, and Peter J. Scambler⁴

¹Department of Genetics, Albert Einstein College of Medicine, Bronx, NY, USA

²Division of Human Genetics, Children's Hospital of Philadelphia and Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA

³Center for Human Genetics, Katholieke Universiteit Leuven (KU Leuven), Leuven, Belgium

⁴Institute of Child Health, University College London, 30 Guilford St, London WC1N 1EH, United Kingdom

Abstract

The 22q11.2 deletion syndrome (22q11.2DS) is a congenital malformation and neuropsychiatric disorder caused by meiotic chromosome rearrangements. One of the goals of this review is to summarize the current state of basic research studies of 22q11.2DS. It highlights efforts to understand the mechanisms responsible for the 22q11.2 deletion that occurs in meiosis. This mechanism involves the four sets of low copy repeats (LCR22) that are dispersed in the 22q11.2 region and the deletion is mediated by non-allelic homologous recombination events. This review also highlights selected genes mapping to the 22q11.2 region that may contribute to the typical clinical findings associated with the disorder and explain that mutations in genes on the remaining allele can uncover rare recessive conditions. Another important aspect of 22q11.2DS is the existence of phenotypic heterogeneity. While some patients are mildly affected, others have severe medical, cognitive and/or psychiatric challenges. Variability may be due in part to the presence of genetic modifiers. This review discusses current genome-wide efforts to identify such modifiers that could shed light on molecular pathways required for normal human development, cognition or behavior.

Keywords

22q11.2 deletion syndrome; chromosome rearrangements; congenital malformation; birth defect syndrome; pharyngeal apparatus; DiGeorge syndrome; velo-cardio-facial syndrome

Clinical aspects of 22q11.2 deletion syndrome

The chromosome 22q11.2 region is susceptible to meiotic chromosome rearrangements leading to congenital malformation syndromes. The best characterized among these is the 22q11.2 deletion syndrome (22q11.2DS; velo-cardio-facial syndrome (MIM#192430) or

*Corresponding Author: Bernice E. Morrow, Department of Genetics, Albert Einstein College of Medicine, 1301 Morris Park Ave, Bronx NY 10461, Bernice.morrow@einstein.yu.edu, Phone: 718-678-1121, Fax: 718-678-1016.

DiGeorge syndrome (MIM#188400). The disorder is the most common among microdeletion syndromes, occurring in ~1/4000 live births (Botto et al., 2003; Devriendt, Fryns, Mortier, van Thienen, & Keymolen, 1998; Goodship, Cross, LiLing, & Wren, 1998) and 1/1000 fetuses (Grati et al., 2015; Wapner et al., 2012). It occurs as a *de novo* 1.5–3 million base pair (Mb) deletion in most individuals (Lindsay et al., 1995; Morrow et al., 1995), although approximately 5% are inherited (McDonald-McGinn et al., 2001). When inherited, there is a 50% recurrence risk with 100% penetrance and wide expressivity. Affected individuals have mild to serious medical features including most often congenital heart disease, immunodeficiency, autoimmune disease, palatal abnormalities, hypocalcemia (often associated with hypoparathyroidism), thyroid disease, gastrointestinal differences, renal anomalies, skeletal anomalies, thrombocytopenia and characteristic facial features (Bassett et al., 2011; McDonald-McGinn et al., 2015). The majority have deficits in cognitive abilities and 25% develop schizophrenia (Bassett & Chow, 1999; Murphy, Jones, & Owen, 1999). Other significant behavioral anomalies occur including attention deficit disorder and anxiety (Biswas & Furniss, 2016; Campbell, McCabe, Melville, Strutt, & Schall, 2015; Niarchou, Martin, Thapar, Owen, & van den Bree, 2015; Vangkilde et al., 2016; Vorstman et al., 2015). Further medical and psychiatric disorders occur less often in affected individuals but at higher frequencies than the general population (Bassett et al., 2011; McDonald-McGinn et al., 2015; Ritter et al., 2015). Most recently, adult patients with 22q11.2DS have developed Parkinson's disease (Boot et al., 2018; Butcher et al., 2013; Rehman, Dhamija, Williams, & Barrett, 2015). This is a newly appreciated complication in association with 22q11.2DS. Studies of the condition provide opportunities to dissect out genetic and environmental risk factors or modifiers within the 22q11.2 region and elsewhere in the genome. Since the condition results from the deletion, it is necessary to understand why the deletion occurs.

Mechanism for meiotic 22q11.2 chromosome rearrangements

The 22q11.2 deletion usually occurs by meiotic non-allelic homologous recombination (NAHR) events between low copy repeats on chromosome 22q11.2 termed LCR22 (Edelmann, Pandita, & Morrow, 1999; Edelmann, Pandita, Spiteri, et al., 1999; Shaikh et al., 2000). Low copy repeats are also referred to as segmental duplications (Bailey et al., 2002). There are eight LCR22s that span the 22q11.2 region termed LCR22A through -H. There are four LCR22s that map to the 3 Mb region associated with the disorder and they are termed LCR22A, -B, -C and -D. In over 90% of patients, the region between LCR22A-D is hemizygotously deleted. This is referred to as the LCR22A-D deletion type. The 1.5 Mb deletion between LCR22A-B is the second most common deletion type, while the 2.0 Mb LCRA-C deletion is least frequent [(Carlson et al., 1997); Figure 1]. LCR22A and LCR22D are the largest in size and have the most homology to each other, making them good targets for NAHR events. The LCR22s are composed of modules harboring pseudogenes that formed during primate evolution by the processes of gene duplication and gene conversion events (Babcock et al., 2003; Babcock et al., 2007; Pavlicek, House, Gentles, Jurka, & Morrow, 2005). Each LCR22 is a complex mosaic of modules that has been challenging to precisely map in humans. This complexity has made it exceedingly difficult to identify the

position of chromosome breakpoints in deleted patients (X. Guo et al., 2016; X. Guo, Freyer, Morrow, & Zheng, 2011).

Efforts to determine the 22q11.2 deletion endpoints

There has been much interest to clone and sequence the position of the chromosome 22q11.2 breakpoints leading to the typical LCR22A-D deletion. Due to the complexity of LCR22 structure, usage of traditional sequencing methods has only been partially successful, as eluded to above (X. Guo et al., 2016). This technical challenge can potentially be alleviated by the application of optical genome mapping techniques. One approach utilizes long single molecules imaged in nanochannel arrays to generate molecular maps (Lam et al., 2012; Mak et al., 2016). Another approach is molecular combing with targeted probes flanking and targeting the LCR22 subunits, which will visualize the probe patterns along DNA fibers. The stretching of chromatin is a particular process needed to form the fibers (Michalet et al., 1997). By leveraging the increased sensitivity afforded by long single molecule optical maps, coupled with low coverage whole-genome sequence, the previously unmappable architecture and variation of the LCR22s and surrounding regions might be elucidated. This will provide enhanced insight into the mechanisms responsible for the deletion and its associated phenotypes. Further, it will likely provide an approach to deletion breakpoint detection in a clinical setting.

Clinical testing for the 22q11.2 deletion

There are several different molecular tools that have been developed for clinical purposes to identify the 22q11.2 deletion. Classic testing by fluorescence *in situ* hybridization (FISH) utilizes commercial probes such as N25 or TUPLE (Figure 1). The two FISH probes map to the LCR22A-B region, thus the probes will identify typical deletions, but would miss atypical nested deletions that occur outside the A-B region. Multiplex Ligation-dependent Probe Amplification (MLPA) has probes that are spaced throughout the 22q11.2 region and can be used to identify typical and atypical deletions (Fernandez et al., 2005; Vorstman et al., 2006). MLPA is most useful to confirm a suspected diagnosis because it only probes the 22q11.2 region. Clinical genome-wide microarray testing (single nucleotide polymorphism/SNP genotyping microarray or microarray comparative genome hybridization-CGH) is useful when it is not possible to make a definitive diagnosis based upon clinical presentation or when MLPA is not clinically available. One of the unexpected discoveries of genome-wide testing is the expansion of the known phenotypic spectrum in patients with 22q11.2DS. Further, it has identified atypical nested 22q11.2 deletions such as the LCR22B-D or C-D deletions. These patients have some related features to those with the typical deletions, but they occur with reduced penetrance (Racedo et al., 2015; Rump et al., 2014). What is truly fascinating is that the LCR22A-B deleted region does not overlap with the LCR22B-D or C-D region, ascribing haploinsufficiency of different genes to some similar phenotypes. The extent of the similarity of phenotypes should be taken with a word of caution because more patients with less frequently occurring deletions need to be analyzed to fully appreciate the range or severity of anomalies. The existence of atypical deletions underscores the importance of evaluating deletion size as well as of understanding

the function of genes throughout the 22q11.2 region to delineate their role in individual abnormalities and the overall phenotype of the disorder.

Genes on 22q11.2 that cause congenital malformations

There are 45 known protein coding genes, seven miRNA and ten non-coding genes that map to the 3 Mb, 22q11.2 region, as well as additional predicted coding and non-coding genes as shown in Figure 1. Among the genes mapping to the LCR22A-B region is *TBX1*, which encodes a T-box type of transcription factor. This gene has received much attention for a major role in medical aspects of the disorder. Heterozygous mutations within *TBX1* have been identified in patients with similar defects as occurs in those with 22q11.2DS (Castellanos, Xie, Zheng, Cvekl, & Morrow, 2014; Gong et al., 2001; Griffin et al., 2010; Ogata et al., 2014; Pan et al., 2015; Stoller & Epstein, 2005; Torres-Juan et al., 2007; Xu et al., 2014; Yagi et al., 2003; Zweier, Sticht, Aydin-Yaylagul, Campbell, & Rauch, 2007). Supporting this, and occurring chronologically before mutations in patients were discovered, mouse models in which *Tbx1* was inactivated were generated (Jerome & Papaioannou, 2001; Lindsay et al., 2001; Merscher et al., 2001). Inactivation of one allele resulted in mild cardiovascular defects, but inactivation of both alleles resulted in cleft palate, thymic and parathyroid gland aplasia as well as cardiovascular defects (Jerome & Papaioannou, 2001; Lindsay et al., 2001; Merscher et al., 2001). A series of alleles was generated with varying expression levels of *Tbx1* and it was found that the gene is very sensitive to changes in copy number, such as what occurs when one allele is deleted in humans (Baldini, 2006; Z. Zhang & Baldini, 2008). Of interest, it was discovered that different tissues and organs have different degrees of sensitivity to *Tbx1* dosage and suggests that altered regulation of its expression could explain phenotypic variability in patients (Z. Zhang & Baldini, 2008). Further, overexpression of human or mouse *Tbx1* is able to genetically rescue malformations that occur in mouse deletion models equivalent to the LCR22A-B deletion (Lindsay et al., 2001; Merscher et al., 2001). The discovery of *TBX1* as a major player in medical aspects of 22q11.2DS has allowed the exploration of genetic pathways upstream and downstream of *TBX1* needed for normal embryonic development (Ivins et al., 2005; Liao et al., 2008).

In mammals, *Tbx1* is expressed in the embryonic cells that will form the craniofacial region, thymus and parathyroid glands, aortic arch as well as cardiac outflow tract. These are the structures affected in 22q11.2DS and in *Tbx1* loss of function mouse embryos. The *Tbx1* expressing cells lie within the embryonic pharyngeal apparatus (Figure 2), which is a structure that will form gills in fish but becomes dramatically remodelled in mammals. *Tbx1* is expressed and functions in all three germ layers of the pharyngeal apparatus, namely the endoderm (Arnold et al., 2006; Jackson, Kasah, Mansour, Morrow, & Basson, 2014; Z. Zhang et al., 2005), mesoderm (Z. Zhang, Huynh, & Baldini, 2006) and ectoderm (Z. Zhang et al., 2005). These cells communicate signals to neural crest cells. Neural crest cells comprise a population of cells that delaminates and migrates from the neural tube. These cells make a major contribution to morphogenesis of the structures affected in 22q11.2DS (Calmont et al., 2009). This illustrates the complexity of the tissue interactions that are required for morphogenesis of the derivative structures from the pharyngeal apparatus (Papangelis & Scambler, 2013). Recently, direct downstream transcriptional target genes of *TBX1* protein were discovered and a link to chromatin modification in connection with

TBX1 was identified (Baldini, Fulcoli, & Illingworth, 2017; Fulcoli et al., 2016). This work has led to the hypothesis that inhibition of histone demethylases might rescue the CHD phenotype in *Tbx1* loss of function embryos (Baldini et al., 2017; Fulcoli et al., 2016).

Besides *TBX1*, there is another gene that may contribute to the medical findings in 22q11.2DS and the gene is termed *CRKL* (CRK like proto-oncogene, adaptor protein). *CRKL* maps to the LCR22C-D region and it encodes a cytoplasmic adaptor protein involved in growth factor signalling. *Crkl* is required for development of the thymus and parathyroid glands, aortic arch and heart (Guris, Duester, Papaioannou, & Imamoto, 2006; Guris, Fantes, Tara, Druker, & Imamoto, 2001; Moon et al., 2006). Of interest, inactivation of both alleles of *Crkl* in the mouse results in similar defects as in *Tbx1* null mutant mice. Mice that have one allele of *Tbx1* and *Crkl* inactivated together have similar defects as in 22q11.2DS patients (Guris et al., 2006; Guris et al., 2001). This supports the idea that the two genes act in the same genetic pathway. Unlike *Tbx1*, whose expression is restricted in specific cells and tissues, *Crkl* is ubiquitously expressed in all cells (Guris et al., 2001). It is hypothesized that *Tbx1* acts upstream of the *Fgf8* (Fibroblast growth factor 8) growth factor gene, and this activates *CRKL* in neural crest cells and leads to activation of downstream signalling (Moon et al., 2006). Recently, it was found that hemizygoty of *CRKL* contributes to genitourinary tract development in humans and animal models, including the kidney (Haller, Mo, Imamoto, & Lamb, 2017; Lopez-Rivera et al., 2017). Although these are not considered the most common of defects in 22q11.2DS, they occur more commonly than the general population. Besides coding genes, non-coding genes, such as miRNAs might also contribute to the etiology of 22q11.2DS.

The miRNAs are small non-coding RNAs that regulate expression of target genes by binding to specific sites in messenger RNAs causing repression of translation or degradation. Another gene of note required for both cardiovascular and brain development or function is *DGCR8* [DiGeorge Critical Region 8; (Chapnik, Sasson, Belloch, & Hornstein, 2012; Earls et al., 2012; Sellier et al., 2014)]. This gene encodes a subunit of a microprocessor complex that mediates the biogenesis of miRNAs (Gregory et al., 2004). Further, there are several miRNA genes that map to the 22q11.2 region (Figure 1) and they have not been studied in detail, as of yet. Another potentially relevant gene is *HIC2* (Hypermethylated In Cancer 2). *HIC2* maps to a small unique genomic region near the distal end of LCR22D and it is not usually deleted in patients. However, some individuals have atypical longer deletions in LCR22D that extend beyond *HIC2* (Dykes et al., 2014). *HIRA* is also of interest, because it encodes a component of a protein complex that deposits the variant histone H3.3 at regulatory regions of genes, thereby modulating gene expression (Dilg et al., 2016; Farrell et al., 1999; Majumder, Syed, Joseph, Scambler, & Dutta, 2015; H. Zhang et al., 2017). Supporting a possible relevant function, conditional inactivation of *Hira* in mouse mesoderm cells causes cardiac defects (Manchineella, Thirivikraman, Basu, & Govindaraju, 2016).

Genes on 22q11.2 that affect the brain or behavior.

The relative importance of individual genes on chromosome 22q11.2 that contribute to cognitive and behavioral problems in patients is still being elucidated. Genes in the nested, LCR22A-B region have been more extensively evaluated than those in the distal, LCR22B-

D region. The LCR22A-B region was identified as the smallest region of overlap between deletion types in 22q11.2DS patients presenting with the typical manifestations of 22q11.2DS, including schizophrenia (Karayiorgou et al., 1995). Patients with LCR22B-D or C-D deletions have only been identified recently due to the clinical utilization of microarrays for genetic testing. Because of the smaller number that have been characterized, it is not known whether schizophrenia is an important feature in such patients. Identifying which gene(s) contribute to these anomalies has been challenging because the great majority of genes in the LCR22A-B region are expressed in the brain (Maynard et al., 2003). In humans, the gene most well-studied for such deficits is *COMT* (Catechol-O-methyltransferase). The COMT protein has a critical role in dopamine neurotransmitter metabolism. Further, there is a commonly occurring coding variant, referred to as Val158Met that affects enzyme activity (Li et al., 1996). While some studies support a role of reduced enzyme activity of *COMT* to cause cognitive and/or behavioural deficits, others do not, and the importance of this functional variation in *COMT* remains controversial (Armando, Papaleo, & Vicari, 2012; Franconi et al., 2016). Another gene that has been extensively studied in humans is *PRODH*, encoding proline dehydrogenase that converts proline to glutamate, involved in neurotransmission. As is true for *COMT*, the role of *PRODH* is not yet definitive (Carmel et al., 2014; Radoeva et al., 2014; Zarchi et al., 2013). Commonly occurring single nucleotide polymorphisms in additional genes have been identified in patients with schizophrenia, but most of the studies were small in size and some of the findings failed replication. Another gene worth mentioning is *PIK4CA*. This gene encodes Phosphatidylinositol 4-kinase alpha and has been considered a candidate for schizophrenia, although this possibility remains controversial (Ikeda et al., 2010; Vorstman et al., 2009). Further, the gene maps outside the LCR22A-B region, considered to be the critical region for schizophrenia on 22q11.2. More studies need to be done on patients with LCR22B-D or C-D deletions to understand the function of genes in this region as risk factors for schizophrenia.

Genes in the LCR22A-B region have been carefully evaluated in mouse models for a possible role in brain development or function (Karayiorgou & Gogos, 2004; Wang, Bryan, LaMantia, & Mendelowitz, 2017). Genes of interest required for brain or behavioral function in mouse models are *Zdhc8* (Zinc finger DHHC-type containing 8; (Mukai et al., 2004)), *Ranbp1* (Ran GTPase-binding protein; (Paronett, Meechan, Karpinski, LaMantia, & Maynard, 2015)), *Rtn4r* (Reticulon 4 receptor; NOGOR; (R. Hsu et al., 2007; Kimura et al., 2017)), and *Dgcr8* (Diamantopoulou et al., 2017; Eom, Bayazitov, Anderson, Yu, & Zakharenko, 2017; Fenelon et al., 2011; Stark et al., 2008). Genes important for mitochondrial function are newly appreciated in mouse models, to have a role in the etiology of schizophrenia (Devaraju & Zakharenko, 2017; Meechan, Maynard, Tucker, & LaMantia, 2011), and specifically, for example, *Mrp140* [Mitochondrial large ribosomal subunit protein 40; (Devaraju et al., 2017)]. Further work needs to be done to understand the relative importance of these genes in humans.

Uncovering of recessive mutations on 22q11.2

Over the years, some subjects have been identified with unusual clinical findings co-occurring with the main phenotypes of 22q11.2DS. One possible explanation is that there is a mutation in a gene on the remaining, haploid allele of 22q11.2 resulting in the co-

occurrence of a recessive disorder. This explanation is exactly what has been found to occur in some patients with 22q11.2DS that also have atypical phenotypes. Several genes within the deleted region have been identified as harboring autosomal recessive mutations and they are listed in Table 1. Five genes, *PRODH* (Afenjar et al., 2007; Bender et al., 2005; Efron, 1965; Goodman, Rutberg, Lin, Pulver, & Thomas, 2000; Jacquet et al., 2003; Jacquet et al., 2002), *SLC25A1* [Solute family carrier 25 member 1 (Edvardson et al., 2013; Majd, King, Smith, & Kunji, 2018; Nota et al., 2013)], *CDC45* [Cell division cycle 45; (Fenwick et al., 2016)], *GPIBB* [Glycoprotein 1b platelet subunit beta; (Budarf et al., 1995; Hayashi & Suzuki, 2000; Kato et al., 2003; Kunishima et al., 2013; Lawrence, McDonald-McGinn, Zackai, & Sullivan, 2003; Ludlow et al., 1996; Roth, 1996; Tang et al., 2004)] and *TANGO2* [Transport and golgi organization 2 homolog; (Kremer et al., 2016; Lalani et al., 2016)], map to the LCR22A-B region. In addition to mutations occurring on the other allele in 22q11.2DS patients, other patients have been reported to have point mutations on both alleles but do not carry the deletion (Table 1). Each recessive disorder has their own characteristic clinical findings as listed in Table 1. *SCARF2* [Scavenger receptor class F member 2; (Bedeschi et al., 2010)] maps to the LCR22B-C region, while *SNAP29* [Synaptosome associated protein 29; (T. Hsu et al., 2017; McDonald-McGinn et al., 2013; Sprecher et al., 2005)] maps to the LCR22C-D region. Separate from these birth defect syndromes, somatic loss of heterozygosity of one allele and a loss of function mutation in *LZTR1* on the other allele predispose individuals to an inherited disorder of multiple schwannomas (Piotrowski et al., 2014).

These findings of recessive disorders and a possible somatic dominant condition, confirm that extreme phenotypic abnormalities observed in a subset of patients with 22q11.2DS can be due to mutations on the non-deleted allele, leading to unmasking of additional conditions. It is also possible that less severe mutations or variations on the remaining allele could contribute to phenotypic variability in 22q11.2DS. On the other hand, recessive mutations in essential genes would likely cause early embryonic lethality, in which we would not be able to identify in the human population.

Phenotypic variability and 22q11.2DS

One of the most challenging features of 22q11.2DS is its phenotypic variability, despite the fact that most patients have the same size, 3 Mb deletion. For example, 60–70% have congenital heart disease, which includes many different aortic arch and/or cardiac outflow tract anomalies (Goldmuntz et al., 1993; McDonald-McGinn et al., 2015; Swillen & McDonald-McGinn, 2015). Other common features include cleft of the muscular palate/velopharyngeal dysfunction, endocrine abnormalities including hypocalcemia, thyroid disease and growth hormone deficiency, immunodeficiency/autoimmune disease, gastroenterological issues, skeletal abnormalities such as scoliosis, as well as, neuropsychiatric and cognitive deficits. As mentioned above, schizophrenia occurs in 25% of individuals with the disorder (Bassett & Chow, 1999; Murphy et al., 1999). Analysis of 21,094 cases with schizophrenia and 20,227 controls without psychiatric disease identified the 22q11.2 deletion as the most significantly associated copy number variation (Marshall et al., 2017). The 22q11.2 deletion is the most common pathogenic copy number variations

associated with schizophrenia. Despite this, most patients with 22q11.2DS do not develop schizophrenia.

One possible explanation for altered phenotypic expression of medical and behavioral disorders, is the existence of other genetic variations in the genome, in addition to the deletion that act as modifiers. Another possible explanation is the occurrence of stochastic events during embryogenesis and a third is the existence of as of yet, unknown environmental exposures in pregnancy. Of interest, monozygotic twins with 22q11.2DS typically have discordant features (Fryer, 1996; Goodship, Cross, Scambler, & Burn, 1995; Halder, Jain, Chaudhary, & Varma, 2012; Hatchwell, 1996; Lu, Chung, Hwang, & Chien, 2001; McDonald-McGinn et al., 2001; Rauch et al., 1998; Singh, Murphy, & O'Reilly, 2002; Vincent et al., 1999; Yamagishi et al., 1998). This implicates stochastic events, epigenetic variation in pregnancy or somatic mutations as also contributing to variation.

Among the possibilities, identifying genetic modifiers on the remaining 22q11.2 allele or elsewhere in the genome are feasible to test in sufficient sized cohorts of affected individuals. This may be useful for identifying modifiers of congenital heart disease because this phenotype is usually available for patients and it is identified soon after birth. For this, firstly, mutations in the coding region of *TBX1* were ruled out as factors that influence cardiovascular phenotypes in a large cohort of 22q11.2DS patients (T. Guo et al., 2011).

In terms of genetic factors, one obvious category to investigate is the presence of second-hit large-sized copy number variations (CNVs). The CNVs might contain genes whose function is sensitive to copy number for various phenotypes. Some may act in the same genetic pathway as 22q11.2 genes, and either exacerbate or suppress individual phenotypes. Affymetrix 6.0 arrays on almost one-thousand subjects with 22q11.2DS revealed a commonly occurring duplication CNV containing the *SLC2A3* (Solute carrier family 3 member 2) gene in individuals with 22q11.2DS with congenital heart disease compared to those with the condition but with normal cardiac and/or aortic arch structures (Mlynarski et al., 2015). Analysis of rare CNVs that alter risk to cardiovascular anomalies has been more challenging, with no specific increased burden of CNVs, but it is possible, when taken together that CNVs harboring genes important for cardiovascular development play a role in this sensitized population (Mlynarski et al., 2016). Recently, rare CNVs were shown to contribute to schizophrenia and 22q11.2DS (Bassett et al., 2017).

Whole exome sequencing on 184 individuals with 22q11DS, in which roughly half had severe cardiac anomalies and half had no defect, identified genes important for chromatin modification as altering risk (T. Guo et al., 2015) as well as additional genes with rare possible damaging variants, for cardiac development (Lin, Zhang, Cai, Morrow, & Zhang, 2017). Examination of whole genome sequence (WGS) in >1,500 subjects with 22q11.2DS is currently underway to identify genetic factors for congenital heart disease as well as for schizophrenia (Gur et al., 2017). The availability of WGS will enable scientists to identify common and rare single nucleotide variations in coding and non-coding regions, as well as large or smaller second-hit CNVs that serve as modifiers. It can be hypothesized that some of the genes or regulatory regions that will be uncovered likely interact with genes that are hemizygotously deleted on the 22q11.2 region.

CONCLUSIONS

Following the discovery of the 22q11.2 deletion in patients, almost 40 years ago, there is still much to learn about molecular aspects of the condition. This includes efforts to determine the mechanism of chromosome 22q11.2 deletions that could lead to development of improved clinical screening methods and understanding the genes responsible for typical as well as atypical phenotypes. Further, 22q11.2DS serves as a model to understand how genetics and the environment can modify the phenotype.

ACKNOWLEDGEMENTS

We would like to thank the families with 22q11.2DS who have participated in molecular genetic studies. This work was supported by grants NIH R01 HL084410 (BSE, BEM, DMM), P01 HD070454 (BSE, BEM, DMM), MH087636 (BSE, DMM), U01 MH101720 (BSE, DMM, JV), R01 HL132577 (BEM) and a Foundation Leducq grant (BEM, PJS). This work was also funded by the British Heart Foundation, PG/09/065/27893 (PJS). This work was made possible by grants from the KUL PFV/10/016 SymBioSys, GOA/12/015 G.0E1117N, the Jerome Lejeune Foundation (project #1665) to JRV. We have no conflicts of interest to declare.

REFERENCES

- Afenjar A, Moutard ML, Doummar D, Guet A, Rabier D, Vermersch AI, ... Rodriguez D (2007). Early neurological phenotype in 4 children with biallelic PRODH mutations. *Brain Dev* 29(9), 547–552. doi:10.1016/j.braindev.2007.01.008 [PubMed: 17412540]
- Armando M, Papaleo F, & Vicari S (2012). COMT implication in cognitive and psychiatric symptoms in chromosome 22q11 microdeletion syndrome: a selective review. *CNS Neurol Disord Drug Targets* 11(3), 273–281. [PubMed: 22483289]
- Arnold JS, Werling U, Braunstein EM, Liao J, Nowotschin S, Edelmann W, ... Morrow BE (2006). Inactivation of Tbx1 in the pharyngeal endoderm results in 22q11DS malformations. *Development* 133(5), 977–987. doi:10.1242/dev.02264 [PubMed: 16452092]
- Babcock M, Pavlicek A, Spiteri E, Kashork CD, Ioshikhes I, Shaffer LG, ... Morrow BE (2003). Shuffling of genes within low-copy repeats on 22q11 (LCR22) by Alu-mediated recombination events during evolution. *Genome Res* 13(12), 2519–2532. doi:10.1101/gr.1549503 [PubMed: 14656960]
- Babcock M, Yatsenko S, Hopkins J, Brenton M, Cao Q, de Jong P, ... Morrow BE (2007). Hominoid lineage specific amplification of low-copy repeats on 22q11.2 (LCR22s) associated with velo-cardio-facial/digeorge syndrome. *Hum Mol Genet* 16(21), 2560–2571. doi:10.1093/hmg/ddm197 [PubMed: 17675367]
- Bailey JA, Yavor AM, Viggiano L, Misceo D, Horvath JE, Archidiacono N, ... Eichler EE (2002). Human-specific duplication and mosaic transcripts: the recent paralogous structure of chromosome 22. *Am J Hum Genet* 70(1), 83–100. doi:10.1086/338458 [PubMed: 11731936]
- Baldini A (2006). The 22q11.2 deletion syndrome: a gene dosage perspective. *ScientificWorldJournal* 6, 1881–1887. doi:10.1100/tsw.2006.317 [PubMed: 17205194]
- Baldini A, Fulcoli FG, & Illingworth E (2017). Tbx1: Transcriptional and Developmental Functions. *Curr Top Dev Biol* 122, 223–243. doi:10.1016/bs.ctdb.2016.08.002 [PubMed: 28057265]
- Bassett AS, & Chow EW (1999). 22q11 deletion syndrome: a genetic subtype of schizophrenia. *Biol Psychiatry* 46(7), 882–891. [PubMed: 10509171]
- Bassett AS, Lowther C, Merico D, Costain G, Chow EWC, van Amelsvoort T, ... Behavior C (2017). Rare Genome-Wide Copy Number Variation and Expression of Schizophrenia in 22q11.2 Deletion Syndrome. *Am J Psychiatry* 174(11), 1054–1063. doi:10.1176/appi.ajp.2017.16121417 [PubMed: 28750581]
- Bassett AS, McDonald-McGinn DM, Devriendt K, Digilio MC, Goldenberg P, Habel A, ... International 22q11.2 Deletion Syndrome, C. (2011). Practical guidelines for managing patients with 22q11.2 deletion syndrome. *J Pediatr* 159(2), 332–339 e331. doi:10.1016/j.jpeds.2011.02.039 [PubMed: 21570089]

- Bedeschi MF, Colombo L, Mari F, Hofmann K, Rauch A, Gentilin B, ... Clerici D (2010). Unmasking of a Recessive SCARF2 Mutation by a 22q11.12 de novo Deletion in a Patient with Van den Ende-Gupta Syndrome. *Mol Syndromol* 1(5), 239–245. doi:10.1159/000328135 [PubMed: 22140376]
- Bender HU, Almashanu S, Steel G, Hu CA, Lin WW, Willis A, ... Valle D (2005). Functional consequences of PRODH missense mutations. *Am J Hum Genet* 76(3), 409–420. doi:10.1086/428142 [PubMed: 15662599]
- Biswas AB, & Furniss F (2016). Cognitive phenotype and psychiatric disorder in 22q11.2 deletion syndrome: A review. *Res Dev Disabil* 53–54, 242–257. doi:10.1016/j.ridd.2016.02.010
- Boot E, Butcher NJ, Udow S, Marras C, Mok KY, Kaneko S, ... International Research Group on 22q, D. S. a. P. s. D. (2018). Typical features of Parkinson disease and diagnostic challenges with microdeletion 22q11.2. *Neurology* 90(23), e2059–e2067. doi:10.1212/WNL.0000000000005660 [PubMed: 29752303]
- Botto LD, May K, Fernhoff PM, Correa A, Coleman K, Rasmussen SA, ... Campbell RM (2003). A population-based study of the 22q11.2 deletion: phenotype, incidence, and contribution to major birth defects in the population. *Pediatrics* 112(1 Pt 1), 101–107. [PubMed: 12837874]
- Budarf ML, Konkle BA, Ludlow LB, Michaud D, Li M, Yamashiro DJ, ... Driscoll DA (1995). Identification of a patient with Bernard-Soulier syndrome and a deletion in the DiGeorge/velo-cardio-facial chromosomal region in 22q11.2. *Hum Mol Genet* 4(4), 763–766. [PubMed: 7633430]
- Butcher NJ, Kiehl TR, Hazrati LN, Chow EW, Rogaeva E, Lang AE, & Bassett AS (2013). Association between early-onset Parkinson disease and 22q11.2 deletion syndrome: identification of a novel genetic form of Parkinson disease and its clinical implications. *JAMA Neurol* 70(11), 1359–1366. doi:10.1001/jamaneurol.2013.3646 [PubMed: 24018986]
- Calmont A, Ivins S, Van Bueren KL, Papangeli I, Kyriakopoulou V, Andrews WD, ... Scambler PJ (2009). Tbx1 controls cardiac neural crest cell migration during arch artery development by regulating Gbx2 expression in the pharyngeal ectoderm. *Development* 136(18), 3173–3183. doi:10.1242/dev.028902 [PubMed: 19700621]
- Campbell LE, McCabe KL, Melville JL, Strutt PA, & Schall U (2015). Social cognition dysfunction in adolescents with 22q11.2 deletion syndrome (velo-cardio-facial syndrome): relationship with executive functioning and social competence/functioning. *J Intellect Disabil Res* 59(9), 845–859. doi:10.1111/jir.12183 [PubMed: 25726953]
- Carlson C, Sirotkin H, Pandita R, Goldberg R, McKie J, Wadey R, ... Morrow BE (1997). Molecular definition of 22q11 deletions in 151 velo-cardio-facial syndrome patients. *Am J Hum Genet* 61(3), 620–629. doi:10.1086/515508 [PubMed: 9326327]
- Carmel M, Zarchi O, Michaelovsky E, Frisch A, Patya M, Green T, ... Weizman A (2014). Association of COMT and PRODH gene variants with intelligence quotient (IQ) and executive functions in 22q11.2DS subjects. *J Psychiatr Res* 56, 28–35. doi:10.1016/j.jpsychires.2014.04.019 [PubMed: 24853458]
- Castellanos R, Xie Q, Zheng D, Cvekl A, & Morrow BE (2014). Mammalian TBX1 preferentially binds and regulates downstream targets via a tandem T-site repeat. *PLoS One* 9(5), e95151. doi:10.1371/journal.pone.0095151 [PubMed: 24797903]
- Chapnik E, Sasson V, Blelloch R, & Hornstein E (2012). Dgcr8 controls neural crest cells survival in cardiovascular development. *Dev Biol* 362(1), 50–56. doi:10.1016/j.ydbio.2011.11.008 [PubMed: 22138056]
- Devaraju P, Yu J, Eddins D, Mellado-Lagarde MM, Earls LR, Westmoreland JJ, ... Zakharenko SS (2017). Haploinsufficiency of the 22q11.2 microdeletion gene Mrpl40 disrupts short-term synaptic plasticity and working memory through dysregulation of mitochondrial calcium. *Mol Psychiatry* 22(9), 1313–1326. doi:10.1038/mp.2016.75 [PubMed: 27184122]
- Devaraju P, & Zakharenko SS (2017). Mitochondria in complex psychiatric disorders: Lessons from mouse models of 22q11.2 deletion syndrome: Hemizygous deletion of several mitochondrial genes in the 22q11.2 genomic region can lead to symptoms associated with neuropsychiatric disease. *Bioessays* 39(2). doi:10.1002/bies.201600177
- Devriendt K, Fryns JP, Mortier G, van Thienen MN, & Keymolen K (1998). The annual incidence of DiGeorge/velocardiofacial syndrome. *J Med Genet* 35(9), 789–790.

- Diamantopoulou A, Sun Z, Mukai J, Xu B, Fenelon K, Karayiorgou M, & Gogos JA (2017). Loss-of-function mutation in *Mir22/Emc10* rescues specific schizophrenia-related phenotypes in a mouse model of the 22q11.2 deletion. *Proc Natl Acad Sci U S A* 114(30), E6127–E6136. doi:10.1073/pnas.1615719114 [PubMed: 28696314]
- Dilg D, Saleh RN, Phelps SE, Rose Y, Dupays L, Murphy C, ... Chagnier AL (2016). HIRA Is Required for Heart Development and Directly Regulates *Tnfr2* and *Tnfr3*. *PLoS One* 11(8), e0161096. doi:10.1371/journal.pone.0161096 [PubMed: 27518902]
- Dykes IM, van Bueren KL, Ashmore RJ, Floss T, Wurst W, Szumska D, ... Scambler PJ (2014). HIC2 is a novel dosage-dependent regulator of cardiac development located within the distal 22q11 deletion syndrome region. *Circ Res* 115(1), 23–31. doi:10.1161/CIRCRESAHA.115.303300 [PubMed: 24748541]
- Earls LR, Fricke RG, Yu J, Berry RB, Baldwin LT, & Zakharenko SS (2012). Age-dependent microRNA control of synaptic plasticity in 22q11 deletion syndrome and schizophrenia. *J Neurosci* 32(41), 14132–14144. doi:10.1523/JNEUROSCI.1312-12.2012 [PubMed: 23055483]
- Edelmann L, Pandita RK, & Morrow BE (1999). Low-copy repeats mediate the common 3-Mb deletion in patients with velo-cardio-facial syndrome. *Am J Hum Genet* 64(4), 1076–1086. [PubMed: 10090893]
- Edelmann L, Pandita RK, Spiteri E, Funke B, Goldberg R, Palanisamy N, ... Morrow BE (1999). A common molecular basis for rearrangement disorders on chromosome 22q11. *Hum Mol Genet* 8(7), 1157–1167. [PubMed: 10369860]
- Edvardson S, Porcelli V, J alas C, Soiferman D, Kellner Y, Shaag A, ... Elpeleg O (2013). Agenesis of corpus callosum and optic nerve hypoplasia due to mutations in *SLC25A1* encoding the mitochondrial citrate transporter. *J Med Genet* 50(4), 240–245. doi:10.1136/jmedgenet-2012-101485 [PubMed: 23393310]
- Efron ML (1965). Familial Hyperprolinemia. Report of a Second Case, Associated with Congenital Renal Malformations, Hereditary Hematuria and Mild Mental Retardation, with Demonstration of an Enzyme Defect. *N Engl J Med* 272, 1243–1254. doi:10.1056/NEJM196506172722401 [PubMed: 14290545]
- Eom TY, Bayazitov IT, Anderson K, Yu J, & Zakharenko SS (2017). Schizophrenia-Related Microdeletion Impairs Emotional Memory through MicroRNA-Dependent Disruption of Thalamic Inputs to the Amygdala. *Cell Rep* 19(8), 1532–1544. doi:10.1016/j.celrep.2017.05.002 [PubMed: 28538174]
- Farrell MJ, Stadt H, Wallis KT, Scambler P, Hixon RL, Wolfe R, ... Kirby ML (1999). HIRA, a DiGeorge syndrome candidate gene, is required for cardiac outflow tract septation. *Circ Res* 84(2), 127–135. [PubMed: 9933243]
- Fenelon K, Mukai J, Xu B, Hsu PK, Drew LJ, Karayiorgou M, ... Gogos JA (2011). Deficiency of *Dgcr8*, a gene disrupted by the 22q11.2 microdeletion, results in altered short-term plasticity in the prefrontal cortex. *Proc Natl Acad Sci U S A* 108(11), 4447–4452. doi:10.1073/pnas.1101219108 [PubMed: 21368174]
- Fenwick AL, Kliszczak M, Cooper F, Murray J, Sanchez-Pulido L, Twigg SR, ... Bicknell LS (2016). Mutations in *CDC45*, Encoding an Essential Component of the Pre-initiation Complex, Cause Meier-Gorlin Syndrome and Craniosynostosis. *Am J Hum Genet* 99(1), 125–138. doi:10.1016/j.ajhg.2016.05.019 [PubMed: 27374770]
- Fernandez L, Lapunzina P, Arjona D, Lopez Pajares I, Garcia-Guereta L, Elorza D, ... Delicado A (2005). Comparative study of three diagnostic approaches (FISH, STRs and MLPA) in 30 patients with 22q11.2 deletion syndrome. *Clin Genet* 68(4), 373–378. doi:10.1111/j.1399-0004.2005.00493.x [PubMed: 16143025]
- Franconi CP, McDonald-McGinn D, Zackai EH, McNamara MA, Salmons H. t., Moss E, ... Emanuel BS (2016). IQ and hemizyosity for the Val(158) Met functional polymorphism of *COMT* in 22q11DS. *Am J Med Genet B Neuropsychiatr Genet* 171(8), 1112–1115. doi:10.1002/ajmg.b.32492 [PubMed: 27619075]
- Fryer A (1996). Monozygotic twins with 22q11 deletion and discordant phenotypes. *J Med Genet* 33(2), 173.

- Fulcoli FG, Franzese M, Liu X, Zhang Z, Angelini C, & Baldini A (2016). Rebalancing gene haploinsufficiency in vivo by targeting chromatin. *Nat Commun* 7, 11688. doi:10.1038/ncomms11688 [PubMed: 27256596]
- Goldmuntz E, Driscoll D, Budarf ML, Zackai EH, McDonald-McGinn DM, Biegel JA, & Emanuel BS (1993). Microdeletions of chromosomal region 22q11 in patients with congenital conotruncal cardiac defects. *J Med Genet* 30(10), 807–812. [PubMed: 7901419]
- Gong W, Gottlieb S, Collins J, Blescia A, Dietz H, Goldmuntz E, ... Budarf ML (2001). Mutation analysis of TBX1 in non-deleted patients with features of DGS/VCFS or isolated cardiovascular defects. *J Med Genet* 38(12), E45. [PubMed: 11748311]
- Goodman BK, Rutberg J, Lin WW, Pulver AE, & Thomas GH (2000). Hyperprolinaemia in patients with deletion (22)(q11.2) syndrome. *J Inher Metab Dis* 23(8), 847–848. [PubMed: 11196113]
- Goodship J, Cross I, LiLing J, & Wren C (1998). A population study of chromosome 22q11 deletions in infancy. *Arch Dis Child* 79(4), 348–351. [PubMed: 9875047]
- Goodship J, Cross I, Scambler P, & Burn J (1995). Monozygotic twins with chromosome 22q11 deletion and discordant phenotype. *J Med Genet* 32(9), 746–748. [PubMed: 8544199]
- Grati FR, Molina Gomes D, Ferreira JC, Dupont C, Alesi V, Gouas L, ... Vialard F (2015). Prevalence of recurrent pathogenic microdeletions and microduplications in over 9500 pregnancies. *Prenat Diagn* 35(8), 801–809. doi:10.1002/pd.4613 [PubMed: 25962607]
- Gregory RI, Yan KP, Amuthan G, Chendrimada T, Doratotaj B, Cooch N, & Shiekhattar R (2004). The Microprocessor complex mediates the genesis of microRNAs. *Nature* 432(7014), 235–240. doi: 10.1038/nature03120 [PubMed: 15531877]
- Griffin HR, Topf A, Glen E, Zweier C, Stuart AG, Parsons J, ... Goodship JA (2010). Systematic survey of variants in TBX1 in non-syndromic tetralogy of Fallot identifies a novel 57 base pair deletion that reduces transcriptional activity but finds no evidence for association with common variants. *Heart* 96(20), 1651–1655. doi:10.1136/hrt.2010.200121 [PubMed: 20937753]
- Guo T, Chung JH, Wang T, McDonald-McGinn DM, Kates WR, Hawula W, ... Morrow BE (2015). Histone Modifier Genes Alter Conotruncal Heart Phenotypes in 22q11.2 Deletion Syndrome. *Am J Hum Genet* 97(6), 869–877. doi:10.1016/j.ajhg.2015.10.013 [PubMed: 26608785]
- Guo T, McDonald-McGinn D, Blonska A, Shanske A, Bassett AS, Chow E, ... International Chromosome 22q, C. (2011). Genotype and cardiovascular phenotype correlations with TBX1 in 1,022 velo-cardio-facial/DiGeorge/22q11.2 deletion syndrome patients. *Hum Mutat* 32(11), 1278–1289. doi:10.1002/humu.21568 [PubMed: 21796729]
- Guo X, Delio M, Haque N, Castellanos R, Hestand MS, Vermeesch JR, ... Zheng D (2016). Variant discovery and breakpoint region prediction for studying the human 22q11.2 deletion using BAC clone and whole genome sequencing analysis. *Hum Mol Genet* 25(17), 3754–3767. doi: 10.1093/hmg/ddw221 [PubMed: 27436579]
- Guo X, Freyer L, Morrow B, & Zheng D (2011). Characterization of the past and current duplication activities in the human 22q11.2 region. *BMC Genomics* 12, 71. doi:10.1186/1471-2164-12-71 [PubMed: 21269513]
- Gur RE, Bassett AS, McDonald-McGinn DM, Bearden CE, Chow E, Emanuel BS, ... Morrow B (2017). A neurogenetic model for the study of schizophrenia spectrum disorders: the International 22q11.2 Deletion Syndrome Brain Behavior Consortium. *Mol Psychiatry* 22(12), 1664–1672. doi: 10.1038/mp.2017.161 [PubMed: 28761081]
- Guris DL, Duester G, Papaioannou VE, & Imamoto A (2006). Dose-dependent interaction of Tbx1 and Crkl and locally aberrant RA signaling in a model of del22q11 syndrome. *Dev Cell* 10(1), 81–92. doi:10.1016/j.devcel.2005.12.002 [PubMed: 16399080]
- Guris DL, Fantes J, Tara D, Druker BJ, & Imamoto A (2001). Mice lacking the homologue of the human 22q11.2 gene CRKL phenocopy neurocristopathies of DiGeorge syndrome. *Nat Genet* 27(3), 293–298. doi:10.1038/85855 [PubMed: 11242111]
- Halder A, Jain M, Chaudhary I, & Varma B (2012). Chromosome 22q11.2 microdeletion in monozygotic twins with discordant phenotype and deletion size. *Mol Cytogenet* 5(1), 13. doi: 10.1186/1755-8166-5-13 [PubMed: 22413934]

- Haller M, Mo Q, Imamoto A, & Lamb DJ (2017). Murine model indicates 22q11.2 signaling adaptor CRKL is a dosage-sensitive regulator of genitourinary development. *Proc Natl Acad Sci U S A* 114(19), 4981–4986. doi:10.1073/pnas.1619523114 [PubMed: 28439006]
- Hatchwell E (1996). Monozygotic twins with chromosome 22q11 deletion and discordant phenotype. *J Med Genet* 33(3), 261.
- Hayashi T, & Suzuki K (2000). Molecular pathogenesis of Bernard-Soulier syndrome. *Semin Thromb Hemost* 26(1), 53–59.
- Hsu R, Woodroffe A, Lai WS, Cook MN, Mukai J, Dunning JP, ... Gogos JA (2007). Nogo Receptor 1 (RTN4R) as a candidate gene for schizophrenia: analysis using human and mouse genetic approaches. *PLoS One* 2(11), e1234. doi:10.1371/journal.pone.0001234 [PubMed: 18043741]
- Hsu T, Coughlin CC, Monaghan KG, Fiala E, McKinstry RC, Paciorkowski AR, & Shinawi M (2017). CEDNIK: Phenotypic and Molecular Characterization of an Additional Patient and Review of the Literature. *Child Neurol Open* 4, 2329048X17733214. doi:10.1177/2329048X17733214
- Ikeda M, Williams N, Williams HJ, Smith R, Monks S, Owen MJ, ... O'Donovan MC (2010). Failure to confirm association between PIK4CA and psychosis in 22q11.2 deletion syndrome. *Am J Med Genet B Neuropsychiatr Genet* 153B(4), 980–982. doi:10.1002/ajmg.b.31060 [PubMed: 20052689]
- Invins S, Lammerts van Beuren K, Roberts C, James C, Lindsay E, Baldini A, ... Scambler PJ (2005). Microarray analysis detects differentially expressed genes in the pharyngeal region of mice lacking Tbx1. *Dev Biol* 285(2), 554–569. doi:10.1016/j.ydbio.2005.06.026 [PubMed: 16109395]
- Jackson A, Kasah S, Mansour SL, Morrow B, & Basson MA (2014). Endoderm-specific deletion of Tbx1 reveals an FGF-independent role for Tbx1 in pharyngeal apparatus morphogenesis. *Dev Dyn* 243(9), 1143–1151. doi:10.1002/dvdy.24147 [PubMed: 24812002]
- Jacquet H, Berthelot J, Bonnemains C, Simard G, Saugier-Verber P, Raux G, ... Frebourg T (2003). The severe form of type I hyperprolinaemia results from homozygous inactivation of the PRODH gene. *J Med Genet* 40(1), e7. [PubMed: 12525555]
- Jacquet H, Raux G, Thibaut F, Hecketsweiler B, Houy E, Demilly C, ... Frebourg T (2002). PRODH mutations and hyperprolinemia in a subset of schizophrenic patients. *Hum Mol Genet* 11(19), 2243–2249. [PubMed: 12217952]
- Jerome LA, & Papaioannou VE (2001). DiGeorge syndrome phenotype in mice mutant for the T-box gene, Tbx1. *Nat Genet* 27(3), 286–291. doi:10.1038/85845 [PubMed: 11242110]
- Karayorgou M, & Gogos JA (2004). The molecular genetics of the 22q11-associated schizophrenia. *Brain Res Mol Brain Res* 132(2), 95–104. doi:10.1016/j.molbrainres.2004.09.029 [PubMed: 15582150]
- Karayorgou M, Morris MA, Morrow B, Shprintzen RJ, Goldberg R, Borrow J, ... et al. (1995). Schizophrenia susceptibility associated with interstitial deletions of chromosome 22q11. *Proc Natl Acad Sci U S A* 92(17), 7612–7616. [PubMed: 7644464]
- Kato T, Kosaka K, Kimura M, Imamura S, Yamada O, Iwai K, ... Matsuoka R (2003). Thrombocytopenia in patients with 22q11.2 deletion syndrome and its association with glycoprotein Ib-beta. *Genet Med* 5(2), 113–119. doi:10.1097/01.GIM.0000056828.03164.30 [PubMed: 12644781]
- Kimura H, Fujita Y, Kawabata T, Ishizuka K, Wang C, Iwayama Y, ... Ozaki N (2017). A novel rare variant R292H in RTN4R affects growth cone formation and possibly contributes to schizophrenia susceptibility. *Transl Psychiatry* 7(8), e1214. doi:10.1038/tp.2017.170 [PubMed: 28892071]
- Kremer LS, Distelmaier F, Alhaddad B, Hempel M, Iuso A, Kupper C, ... Haack TB (2016). Bi-allelic Truncating Mutations in TANGO2 Cause Infancy-Onset Recurrent Metabolic Crises with Encephalocardiomyopathy. *Am J Hum Genet* 98(2), 358–362. doi:10.1016/j.ajhg.2015.12.009 [PubMed: 26805782]
- Kunishima S, Imai T, Kobayashi R, Kato M, Ogawa S, & Saito H (2013). Bernard-Soulier syndrome caused by a hemizygous GPIIb mutation and 22q11.2 deletion. *Pediatr Int* 55(4), 434–437. doi:10.1111/ped.12105 [PubMed: 23566026]
- Lalani SR, Liu P, Rosenfeld JA, Watkin LB, Chiang T, Leduc MS, ... Yang Y (2016). Recurrent Muscle Weakness with Rhabdomyolysis, Metabolic Crises, and Cardiac Arrhythmia Due to Bi-allelic

- TANGO2 Mutations. *Am J Hum Genet* 98(2), 347–357. doi:10.1016/j.ajhg.2015.12.008 [PubMed: 26805781]
- Lam ET, Hastie A, Lin C, Ehrlich D, Das SK, Austin MD, ... Kwok PY (2012). Genome mapping on nanochannel arrays for structural variation analysis and sequence assembly. *Nat Biotechnol* 30(8), 771–776. doi:10.1038/nbt.2303 [PubMed: 22797562]
- Lawrence S, McDonald-McGinn DM, Zackai E, & Sullivan KE (2003). Thrombocytopenia in patients with chromosome 22q11.2 deletion syndrome. *J Pediatr* 143(2), 277–278. doi:10.1067/S0022-3476(03)00248-8 [PubMed: 12970648]
- Li T, Sham PC, Vallada H, Xie T, Tang X, Murray RM, ... Collier DA (1996). Preferential transmission of the high activity allele of COMT in schizophrenia. *Psychiatr Genet* 6(3), 131–133. [PubMed: 8902889]
- Liao J, Aggarwal VS, Nowotschin S, Bondarev A, Lipner S, & Morrow BE (2008). Identification of downstream genetic pathways of Tbx1 in the second heart field. *Dev Biol* 316(2), 524–537. doi: 10.1016/j.ydbio.2008.01.037 [PubMed: 18328475]
- Lin JR, Zhang Q, Cai Y, Morrow BE, & Zhang ZD (2017). Integrated rare variant-based risk gene prioritization in disease case-control sequencing studies. *PLoS Genet* 13(12), e1007142. doi: 10.1371/journal.pgen.1007142 [PubMed: 29281626]
- Lindsay EA, Goldberg R, Jurecic V, Morrow B, Carlson C, Kucherlapati RS, ... Baldini A (1995). Velo-cardio-facial syndrome: frequency and extent of 22q11 deletions. *Am J Med Genet* 57(3), 514–522. doi:10.1002/ajmg.1320570339 [PubMed: 7677167]
- Lindsay EA, Vitelli F, Su H, Morishima M, Huynh T, Pramparo T, ... Baldini A (2001). Tbx1 haploinsufficiency in the DiGeorge syndrome region causes aortic arch defects in mice. *Nature* 410(6824), 97–101. doi:10.1038/35065105 [PubMed: 11242049]
- Lopez-Rivera E, Liu YP, Verbitsky M, Anderson BR, Capone VP, Otto EA, ... Sanna-Cherchi S (2017). Genetic Drivers of Kidney Defects in the DiGeorge Syndrome. *N Engl J Med* 376(8), 742–754. doi:10.1056/NEJMoa1609009 [PubMed: 28121514]
- Lu JH, Chung MY, Hwang B, & Chien HP (2001). Monozygotic twins with chromosome 22q11 microdeletion and discordant phenotypes in cardiovascular patterning. *Pediatr Cardiol* 22(3), 260–263. doi:10.1007/s002460010219 [PubMed: 11343161]
- Ludlow LB, Schick BP, Budarf ML, Driscoll DA, Zackai EH, Cohen A, & Konkle BA (1996). Identification of a mutation in a GATA binding site of the platelet glycoprotein Ibbeta promoter resulting in the Bernard-Soulier syndrome. *J Biol Chem* 271(36), 22076–22080. [PubMed: 8703016]
- Majd H, King MS, Smith AC, & Kunji ERS (2018). Pathogenic mutations of the human mitochondrial citrate carrier SLC25A1 lead to impaired citrate export required for lipid, dolichol, ubiquinone and sterol synthesis. *Biochim Biophys Acta* 1859(1), 1–7. doi:10.1016/j.bbabo.2017.10.002
- Majumder A, Syed KM, Joseph S, Scambler PJ, & Dutta D (2015). Histone Chaperone HIRA in Regulation of Transcription Factor RUNX1. *J Biol Chem* 290(21), 13053–13063. doi:10.1074/jbc.M114.615492 [PubMed: 25847244]
- Mak AC, Lai YY, Lam ET, Kwok TP, Leung AK, Poon A, ... Kwok PY (2016). Genome-Wide Structural Variation Detection by Genome Mapping on Nanochannel Arrays. *Genetics* 202(1), 351–362. doi:10.1534/genetics.115.183483 [PubMed: 26510793]
- Manchineella S, Thiruvikraman G, Basu B, & Govindaraju T (2016). Surface-Functionalized Silk Fibroin Films as a Platform To Guide Neuron-like Differentiation of Human Mesenchymal Stem Cells. *ACS Appl Mater Interfaces* 8(35), 22849–22859. doi:10.1021/acsami.6b06403 [PubMed: 27518901]
- Marshall CR, Howrigan DP, Merico D, Thiruvahindrapuram B, Wu W, Greer DS, ... Schizophrenia Working Groups of the Psychiatric Genomics C. (2017). Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects. *Nat Genet* 49(1), 27–35. doi: 10.1038/ng.3725 [PubMed: 27869829]
- Maynard TM, Haskell GT, Peters AZ, Sikich L, Lieberman JA, & LaMantia AS (2003). A comprehensive analysis of 22q11 gene expression in the developing and adult brain. *Proc Natl Acad Sci U S A* 100(24), 14433–14438. doi:10.1073/pnas.2235651100 [PubMed: 14614146]

- McDonald-McGinn DM, Fahiminiya S, Revil T, Nowakowska BA, Suhl J, Bailey A, ... Jerome-Majewska LA (2013). Hemizygous mutations in SNAP29 unmask autosomal recessive conditions and contribute to atypical findings in patients with 22q11.2DS. *J Med Genet* 50(2), 80–90. doi: 10.1136/jmedgenet-2012-101320 [PubMed: 23231787]
- McDonald-McGinn DM, Sullivan KE, Marino B, Philip N, Swillen A, Vorstman JA, ... Bassett AS (2015). 22q11.2 deletion syndrome. *Nat Rev Dis Primers* 1, 15071. doi:10.1038/nrdp.2015.71 [PubMed: 27189754]
- McDonald-McGinn DM, Tonnesen MK, Laufer-Cahana A, Finucane B, Driscoll DA, Emanuel BS, & Zackai EH (2001). Phenotype of the 22q11.2 deletion in individuals identified through an affected relative: cast a wide FISHing net! *Genet Med* 3(1), 23–29. [PubMed: 11339373]
- Meechan DW, Maynard TM, Tucker ES, & LaMantia AS (2011). Three phases of DiGeorge/22q11 deletion syndrome pathogenesis during brain development: patterning, proliferation, and mitochondrial functions of 22q11 genes. *Int J Dev Neurosci* 29(3), 283–294. doi:10.1016/j.ijdevneu.2010.08.005 [PubMed: 20833244]
- Merscher S, Funke B, Epstein JA, Heyer J, Puech A, Lu MM, ... Kucherlapati R (2001). TBX1 is responsible for cardiovascular defects in velo-cardio-facial/DiGeorge syndrome. *Cell* 104(4), 619–629. [PubMed: 11239417]
- Michalet X, Ekong R, Fougerousse F, Rousseaux S, Schurra C, Hornigold N, ... Bensimon A (1997). Dynamic molecular combing: stretching the whole human genome for high-resolution studies. *Science* 277(5331), 1518–1523. [PubMed: 9278517]
- Mlynarski EE, Sheridan MB, Xie M, Guo T, Racedo SE, McDonald-McGinn DM, ... International Chromosome 22q, C. (2015). Copy-Number Variation of the Glucose Transporter Gene SLC2A3 and Congenital Heart Defects in the 22q11.2 Deletion Syndrome. *Am J Hum Genet* 96(5), 753–764. doi:10.1016/j.ajhg.2015.03.007 [PubMed: 25892112]
- Mlynarski EE, Xie M, Taylor D, Sheridan MB, Guo T, Racedo SE, ... International Chromosome 22q, C. (2016). Rare copy number variants and congenital heart defects in the 22q11.2 deletion syndrome. *Hum Genet* 135(3), 273–285. doi:10.1007/s00439-015-1623-9 [PubMed: 26742502]
- Moon AM, Guris DL, Seo JH, Li L, Hammond J, Talbot A, & Imamoto A (2006). Crkl deficiency disrupts Fgf8 signaling in a mouse model of 22q11 deletion syndromes. *Dev Cell* 10(1), 71–80. doi:10.1016/j.devcel.2005.12.003 [PubMed: 16399079]
- Morrow B, Goldberg R, Carlson C, Das Gupta R, Sirotkin H, Collins J, ... et al. (1995). Molecular definition of the 22q11 deletions in velo-cardio-facial syndrome. *Am J Hum Genet* 56(6), 1391–1403. [PubMed: 7762562]
- Mukai J, Liu H, Burt RA, Swor DE, Lai WS, Karayiorgou M, & Gogos JA (2004). Evidence that the gene encoding ZDHHC8 contributes to the risk of schizophrenia. *Nat Genet* 36(7), 725–731. doi: 10.1038/ng1375 [PubMed: 15184899]
- Murphy KC, Jones LA, & Owen MJ (1999). High rates of schizophrenia in adults with velo-cardio-facial syndrome. *Arch Gen Psychiatry* 56(10), 940–945. [PubMed: 10530637]
- Niarchou M, Martin J, Thapar A, Owen MJ, & van den Bree MB (2015). The clinical presentation of attention deficit-hyperactivity disorder (ADHD) in children with 22q11.2 deletion syndrome. *Am J Med Genet B Neuropsychiatr Genet* 168(8), 730–738. doi:10.1002/ajmg.b.32378 [PubMed: 26400629]
- Nota B, Struys EA, Pop A, Jansen EE, Fernandez Ojeda MR, Kanhai WA, ... Salomons GS (2013). Deficiency in SLC25A1, encoding the mitochondrial citrate carrier, causes combined D-2- and L-2-hydroxyglutaric aciduria. *Am J Hum Genet* 92(4), 627–631. doi:10.1016/j.ajhg.2013.03.009 [PubMed: 23561848]
- Ogata T, Niihori T, Tanaka N, Kawai M, Nagashima T, Funayama R, ... Matsubara Y (2014). TBX1 mutation identified by exome sequencing in a Japanese family with 22q11.2 deletion syndrome-like craniofacial features and hypocalcemia. *PLoS One* 9(3), e91598. doi:10.1371/journal.pone.0091598 [PubMed: 24637876]
- Pan Y, Wang ZG, Liu XY, Zhao H, Zhou N, Zheng GF, ... Yang YQ (2015). A Novel TBX1 Loss-of-Function Mutation Associated with Congenital Heart Disease. *Pediatr Cardiol* 36(7), 1400–1410. doi:10.1007/s00246-015-1173-x [PubMed: 25860641]

- Papangeli I, & Scambler P (2013). The 22q11 deletion: DiGeorge and velocardiiofacial syndromes and the role of TBX1. *Wiley Interdiscip Rev Dev Biol* 2(3), 393–403. doi:10.1002/wdev.75 [PubMed: 23799583]
- Paronett EM, Meechan DW, Karpinski BA, LaMantia AS, & Maynard TM (2015). Ranbp1, Deleted in DiGeorge/22q11.2 Deletion Syndrome, is a Microcephaly Gene That Selectively Disrupts Layer 2/3 Cortical Projection Neuron Generation. *Cereb Cortex* 25(10), 3977–3993. doi:10.1093/cercor/bhu285 [PubMed: 25452572]
- Pavlicek A, House R, Gentles AJ, Jurka J, & Morrow BE (2005). Traffic of genetic information between segmental duplications flanking the typical 22q11.2 deletion in velo-cardio-facial syndrome/DiGeorge syndrome. *Genome Res* 15(11), 1487–1495. doi:10.1101/gr.4281205 [PubMed: 16251458]
- Piotrowski A, Xie J, Liu YF, Poplawski AB, Gomes AR, Madanecki P, ... Messiaen LM (2014). Germline loss-of-function mutations in LZTR1 predispose to an inherited disorder of multiple schwannomas. *Nat Genet* 46(2), 182–187. doi:10.1038/ng.2855 [PubMed: 24362817]
- Racedo SE, McDonald-McGinn DM, Chung JH, Goldmuntz E, Zackai E, Emanuel BS, ... Morrow BE (2015). Mouse and human CRKL is dosage sensitive for cardiac outflow tract formation. *Am J Hum Genet* 96(2), 235–244. doi:10.1016/j.ajhg.2014.12.025 [PubMed: 25658046]
- Radoeva PD, Coman IL, Salazar CA, Gentile KL, Higgins AM, Middleton FA, ... Kates WR (2014). Association between autism spectrum disorder in individuals with velocardiiofacial (22q11.2 deletion) syndrome and PRODH and COMT genotypes. *Psychiatr Genet* 24(6), 269–272. doi:10.1097/YPG.000000000000062 [PubMed: 25325218]
- Rauch A, Hofbeck M, Bahring S, Leipold G, Trautmann U, Singer H, & Pfeiffer RA (1998). Monozygotic twins concordant for Cayler syndrome. *Am J Med Genet* 75(1), 113–117. [PubMed: 9450869]
- Rehman AF, Dhamija R, Williams ES, & Barrett MJ (2015). 22q11.2 deletion syndrome presenting with early-onset Parkinson's disease. *Mov Disord* 30(9), 1289–1290. doi:10.1002/mds.26305 [PubMed: 26195290]
- Ritter DI, Haines K, Cheung H, Davis CF, Lau CC, Berg JS, ... Plon SE (2015). Identifying gene disruptions in novel balanced de novo constitutional translocations in childhood cancer patients by whole-genome sequencing. *Genet Med* 17(10), 831–835. doi:10.1038/gim.2014.189 [PubMed: 25569436]
- Roth GJ (1996). Molecular defects in the Bernard-Soulier syndrome: assessment of receptor genes, transcripts and proteins. *C R Acad Sci III* 319(9), 819–826.
- Rump P, de Leeuw N, van Essen AJ, Verschuuren-Bemelmans CC, Veenstra-Knol HE, Swinkels ME, ... van Ravenswaaij-Arts CM (2014). Central 22q11.2 deletions. *Am J Med Genet A* 164A(11), 2707–2723. doi:10.1002/ajmg.a.36711 [PubMed: 25123976]
- Sellier C, Hwang VJ, Dandekar R, Durbin-Johnson B, Charlet-Berguerand N, Ander BP, ... Tassone F (2014). Decreased DGCR8 expression and miRNA dysregulation in individuals with 22q11.2 deletion syndrome. *PLoS One* 9(8), e103884. doi:10.1371/journal.pone.0103884 [PubMed: 25084529]
- Shaikh TH, Kurahashi H, Saitta SC, O'Hare AM, Hu P, Roe BA, ... Emanuel BS (2000). Chromosome 22-specific low copy repeats and the 22q11.2 deletion syndrome: genomic organization and deletion endpoint analysis. *Hum Mol Genet* 9(4), 489–501. [PubMed: 10699172]
- Singh SM, Murphy B, & O'Reilly R (2002). Monozygotic twins with chromosome 22q11 deletion and discordant phenotypes: updates with an epigenetic hypothesis. *J Med Genet* 39(11), e71. [PubMed: 12414833]
- Sprecher E, Ishida-Yamamoto A, Mizrahi-Koren M, Rapaport D, Goldsher D, Indelman M, ... Mandel H (2005). A mutation in SNAP29, coding for a SNARE protein involved in intracellular trafficking, causes a novel neurocutaneous syndrome characterized by cerebral dysgenesis, neuropathy, ichthyosis, and palmoplantar keratoderma. *Am J Hum Genet* 77(2), 242–251. doi:10.1086/432556 [PubMed: 15968592]
- Stark KL, Xu B, Bagchi A, Lai WS, Liu H, Hsu R, ... Gogos JA (2008). Altered brain microRNA biogenesis contributes to phenotypic deficits in a 22q11-deletion mouse model. *Nat Genet* 40(6), 751–760. doi:10.1038/ng.138 [PubMed: 18469815]

- Stoller JZ, & Epstein JA (2005). Identification of a novel nuclear localization signal in Tbx1 that is deleted in DiGeorge syndrome patients harboring the 1223delC mutation. *Hum Mol Genet* 14(7), 885–892. doi:10.1093/hmg/ddi081 [PubMed: 15703190]
- Swillen A, & McDonald-McGinn D (2015). Developmental trajectories in 22q11.2 deletion. *Am J Med Genet C Semin Med Genet* 169(2), 172–181. doi:10.1002/ajmg.c.31435 [PubMed: 25989227]
- Tang J, Stern-Nezer S, Liu PC, Matyakhina L, Riordan M, Luban NL, ... Kaler SG (2004). Mutation in the leucine-rich repeat C-flanking region of platelet glycoprotein Ib beta impairs assembly of von Willebrand factor receptor. *Thromb Haemost* 92(1), 75–88. doi:10.1160/TH04-02-0071 [PubMed: 15213848]
- Torres-Juan L, Rosell J, Morla M, Vidal-Pou C, Garcia-Algas F, de la Fuente MA, ... Heine-Suner D (2007). Mutations in TBX1 genocopy the 22q11.2 deletion and duplication syndromes: a new susceptibility factor for mental retardation. *Eur J Hum Genet* 15(6), 658–663. doi:10.1038/sj.ejhg.5201819 [PubMed: 17377518]
- Vangkilde A, Jepsen JR, Schmock H, Olesen C, Arnarsdottir S, Baare WF, ... Olsen L (2016). Associations between social cognition, skills, and function and subclinical negative and positive symptoms in 22q11.2 deletion syndrome. *J Neurodev Disord* 8, 42. doi:10.1186/s11689-016-9175-4 [PubMed: 27891188]
- Vincent MC, Heitz F, Tricoire J, Bourrouillou G, Kuhlein E, Rolland M, & Calvas P (1999). 22q11 deletion in DGS/VCFS monozygotic twins with discordant phenotypes. *Genet Couns* 10(1), 43–49. [PubMed: 10191428]
- Vorstman JA, Breetvelt EJ, Duijff SN, Eliez S, Schneider M, Jalbrzikowski M, ... Behavior in 22q11.2 Deletion, S. (2015). Cognitive decline preceding the onset of psychosis in patients with 22q11.2 deletion syndrome. *JAMA Psychiatry* 72(4), 377–385. doi:10.1001/jamapsychiatry.2014.2671 [PubMed: 25715178]
- Vorstman JA, Chow EW, Ophoff RA, van Engeland H, Beemer FA, Kahn RS, ... Bassett AS (2009). Association of the PIK4CA schizophrenia-susceptibility gene in adults with the 22q11.2 deletion syndrome. *Am J Med Genet B Neuropsychiatr Genet* 150B(3), 430–433. doi:10.1002/ajmg.b.30827 [PubMed: 18646052]
- Vorstman JA, Jalali GR, Rappaport EF, Hacker AM, Scott C, & Emanuel BS (2006). MLPA: a rapid, reliable, and sensitive method for detection and analysis of abnormalities of 22q. *Hum Mutat* 27(8), 814–821. doi:10.1002/humu.20330 [PubMed: 16791841]
- Wang X, Bryan C, LaMantia AS, & Mendelowitz D (2017). Altered neurobiological function of brainstem hypoglossal neurons in DiGeorge/22q11.2 Deletion Syndrome. *Neuroscience* 359, 1–7. doi:10.1016/j.neuroscience.2017.06.057 [PubMed: 28687307]
- Wapner RJ, Martin CL, Levy B, Ballif BC, Eng CM, Zachary JM, ... Jackson L (2012). Chromosomal microarray versus karyotyping for prenatal diagnosis. *N Engl J Med* 367(23), 2175–2184. doi:10.1056/NEJMoa1203382 [PubMed: 23215555]
- Xu YJ, Chen S, Zhang J, Fang SH, Guo QQ, Wang J, ... Sun K (2014). Novel TBX1 loss-of-function mutation causes isolated conotruncal heart defects in Chinese patients without 22q11.2 deletion. *BMC Med Genet* 15, 78. doi:10.1186/1471-2350-15-78 [PubMed: 24998776]
- Yagi H, Furutani Y, Hamada H, Sasaki T, Asakawa S, Minoshima S, ... Matsuoka R (2003). Role of TBX1 in human del22q11.2 syndrome. *Lancet* 362(9393), 1366–1373. [PubMed: 14585638]
- Yamagishi H, Ishii C, Maeda J, Kojima Y, Matsuoka R, Kimura M, ... Matsuo N (1998). Phenotypic discordance in monozygotic twins with 22q11.2 deletion. *Am J Med Genet* 78(4), 319–321. [PubMed: 9714432]
- Zarchi O, Carmel M, Avni C, Attias J, Frisch A, Michaelovsky E, ... Gothelf D (2013). Schizophrenia-like neurophysiological abnormalities in 22q11.2 deletion syndrome and their association to COMT and PRODH genotypes. *J Psychiatr Res* 47(11), 1623–1629. doi:10.1016/j.jpsychires.2013.07.004 [PubMed: 23910792]
- Zhang H, Gan H, Wang Z, Lee JH, Zhou H, Ordog T, ... Zhang Z (2017). RPA Interacts with HIRA and Regulates H3.3 Deposition at Gene Regulatory Elements in Mammalian Cells. *Mol Cell* 65(2), 272–284. doi:10.1016/j.molcel.2016.11.030 [PubMed: 28107649]

- Zhang Z, & Baldini A (2008). In vivo response to high-resolution variation of Tbx1 mRNA dosage. *Hum Mol Genet* 17(1), 150–157. doi:10.1093/hmg/ddm291 [PubMed: 17916582]
- Zhang Z, Cerrato F, Xu H, Vitelli F, Morishima M, Vincentz J, ... Lindsay E (2005). Tbx1 expression in pharyngeal epithelia is necessary for pharyngeal arch artery development. *Development* 132(23), 5307–5315. doi:10.1242/dev.02086 [PubMed: 16284121]
- Zhang Z, Huynh T, & Baldini A (2006). Mesodermal expression of Tbx1 is necessary and sufficient for pharyngeal arch and cardiac outflow tract development. *Development* 133(18), 3587–3595. doi:10.1242/dev.02539 [PubMed: 16914493]
- Zweier C, Sticht H, Aydin-Yaylagul I, Campbell CE, & Rauch A (2007). Human TBX1 missense mutations cause gain of function resulting in the same phenotype as 22q11.2 deletions. *Am J Hum Genet* 80(3), 510–517. doi:10.1086/511993 [PubMed: 17273972]




Figure 1. The 22q11.2 region.

This image was modified from a previously published image (McDonald-McGinn et al., 2015). The 3 Mb 22q11.2 region (hg19 assembly, coordinates) is shown as a line that spans the 22q11.2 region, distal to the centromere (Cen) and harbors four sets of low copy repeats (LCR22), termed LCR22A, -B, -C and -D (gray boxes). The position of clinical diagnostic probes, N25 and TUPLE, for clinical fluorescence *in situ* hybridization (FISH) testing are shown (green boxes). Most of the known coding and non-coding genes that span the interval are shown below the line representing the 22q11.2 region. *TBX1* is indicated in blue font. Genes associated with recessive genetic conditions are indicated in red font. Non-coding genes are indicated with a star. The size and position of 22q11.2 deletions are indicated (gray boxes). The frequency of deletions were obtained from McDonald-McGinn and colleagues in the Special AJMG Issue.




Figure 2. Embryonic development of the pharyngeal apparatus into adult structures.

Cartoon of a lateral view of a mouse embryo at stage day (E) 10.5 in development. The head is shown on top and the tail can be visualized as it twists around the body of the embryo. The pharyngeal apparatus is highlighted in light blue with individual arches (PA) and their derivative structures indicated on the left side (arrows). The outflow tract (OFT), right ventricle (RV), forelimb (FL) and hindlimb (HL) are indicated. Cells migrate from the pharyngeal apparatus into the cardiac OFT to form the aorta and pulmonary trunk during later stages of embryogenesis.

Table 1.

Recessive mutations in genes on the 22q11.2 region.

Each gene is listed with respect to the map location and to the position of the LCR22s. The genomic coordinates in the hg19 genome assembly is listed in the second column. The name of the genetic syndrome caused by recessive mutations is listed as is the Online Mendelian Inheritance in Man (MIM) number. Characteristic clinical features of each disorder are shown. The references used to create the table are listed by PMID (PubMed ID) in the column on the right and are cited in the text.

Gene name	Map position (hg19 assembly)	Disease name	MIM #	22q11.2DS+mutation	Phenotype	PMID
<i>PRODH</i>	A-B; (chr22:18,900,287–18,924,066)	Hyperprolinemia Type 1	239500	YES	Neurological deficits, psychomotor delay, hypotonia, seizures	11196113; 12217952; 12525555; 14290545; 15662599; 17412540
<i>SLC25A1</i>	A-B (chr22:19,163,088–19,166,338)	D2L2AD syndrome	615182	YES	Encephalopathy, severe muscular weakness, seizures, respiratory distress, failed psychomotor development, early death	23393310, 23561848, 29031613
<i>CDC45</i>	A-B (chr22:19,467,414–19,508,135)	Meier-Gorlin syndrome 7	617063	NO	Craniosynostosis, imperforate anus, limb abnormalities, short stature, absent patellae and microtia	27374770
<i>GPIBB</i>	A-B; (chr22:19,705,992–19,712,297)	Bernard-Soulier syndrome	231200	YES	Hematologic disease; thrombocytopenia; increased megakaryocytes	8952885; 10805283; 23566026
<i>TANGO2</i>	A-B (chr22:20,008,631–20,053,447)	MECRN syndrome	616878	NO	Recurrent metabolic crises with encephalocardiomyopathy that includes rhabdomyolysis, neurodegeneration, hearing loss, thyroid disease, hypoglycemia, seizures, dystonia and sudden death	26805781; 26805782
<i>SCARF2</i>	B-C (chr22:20,778,874–20,792,146)	van den Ende-Gupta syndrome	609920	YES	Contractural arachnodactyly, hooked clavicles, joint dislocations and blepharophimosis	22140376
<i>SNAP29</i>	C-D (chr22:21,213,292–21,245,501)	CEDNIK Syndrome	609528	YES	Cerebral dysgenesis, neuropathy, ichthyosis and keratoderma	15968592; 23231787; 29051910